HACOR评分对慢性阻塞性肺疾病合并肺性脑病无创正压通气临床结局的预测价值
该前瞻性研究纳入河南省人民医院2017年1月1日至2021年6月1日收治的51例COPD合并肺性脑病并初始接受无创正压通气的患者,记录不同时间点HACOR评分及临床结局。结果显示70.59%患者无创通气成功并最终出院,29.41%失败转为有创通气,其中早期失败19.61%、晚期失败9.80%。失败组无创通气1-2小时HACOR评分显著高于成功组,ROC曲线AUC为0.686(95%CI 0.504-0.868),最佳截断值10.50时敏感度60.03%、特异度86.10%、阳性预测值91.23%、阴性预测值47.21%。结论认为HACOR评分对预测COPD合并肺性脑病患者无创通气失败有价值。
要点
- 51例COPD合并肺性脑病患者中,无创通气成功并最终出院36例(70.59%),失败转有创通气15例(29.41%)。
- 失败组无创通气1-2小时HACOR评分显著高于成功组[10.47(6.00, 16.00)vs. 6.00(3.25, 8.00),P<0.05]。
- 无创通气前及3-6小时HACOR评分两组无显著差异。
- 1-2小时HACOR评分预测无创通气失败的AUC为0.686(95%CI 0.504-0.868),最佳截断值10.50。
- 截断值10.50时敏感度60.03%、特异度86.10%、阳性预测值91.23%、阴性预测值47.21%。
适用人群与场景
- 河南省人民医院2017年1月1日至2021年6月1日收治的COPD合并肺性脑病并初始接受无创正压通气的患者。
- 排除标准原文未报告;共评估630例,最终纳入51例,其中男42例(82.35%)、女9例(17.65%),中位年龄70.0(62.0, 78.0)岁。
诊断标准与关键阈值
- 无创通气治疗失败定义为需要气管插管;早期失败定义为治疗48小时内需要气管插管,晚期失败定义为48小时及以后需要气管插管。
- HACOR评分由心率(H)、酸中毒(A)、意识(C)、氧合(O)和呼吸频率(R)组成。
- 无创通气后1-2小时HACOR评分预测无创通气失败的最佳截断值为10.50。
处置流程与药物剂量
- 除无创正压通气外,按指南给予标准内科治疗。
- 记录无创通气后不同时间点HACOR评分、ICU住院时间、总住院时间和临床结局。
红旗征与不能漏的情况
- 无创通气1-2小时HACOR评分≥10.50提示无创通气失败风险高(阳性预测值91.23%),原文以此为预测阈值。
研究设计与关键结果
- 前瞻性研究,纳入51例COPD合并肺性脑病初始接受无创正压通气的患者,无创通气成功并最终出院36例(70.59%),失败转有创通气15例(29.41%),其中早期失败10例(19.61%)、晚期失败5例(9.80%)。
- 无创通气成功组ICU住院时间显著长于失败组[13.0(10.0, 16.0)天 vs. 5.0(3.0, 8.0)天,P<0.01],总住院时间也显著长于失败组[23.0(12.0, 28.0)天 vs. 12.0(9.0, 15.0)天,P<0.01]。
- 无创通气1-2小时失败组HACOR评分显著高于成功组[10.47(6.00, 16.00)vs. 6.00(3.25, 8.00),P<0.05];无创通气前及3-6小时两组HACOR评分无显著差异。
- 1-2小时HACOR评分预测无创通气失败的ROC曲线AUC为0.686(95%CI 0.504-0.868),最佳截断值10.50时敏感度60.03%、特异度86.10%、阳性预测值91.23%、阴性预测值47.21%。
证据类型、等级与局限
- 证据类型:前瞻性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为HACOR评分对预测COPD合并肺性脑病患者无创正压通气失败有价值。
- 对COPD合并肺性脑病初始接受无创正压通气的患者,可在无创通气1-2小时计算HACOR评分,评分≥10.50时无创通气失败风险高(阳性预测值91.23%)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To explore the predictive value of HACOR score [heart rate (H), acidosis (A), consciousness (C), oxygenation (O), and respiratory rate (R)] on the clinical outcome of non-invasive positive pressure ventilation in patients with pulmonary encephalopathy due to chronic obstructive pulmonary disease (COPD).
METHODS: A prospective study was conducted. The patients with COPD combined with pulmonary encephalopathy who were admitted to Henan Provincial People's Hospital from January 1, 2017 to June 1, 2021 and initially received non-invasive positive pressure ventilation were enrolled. Besides non-invasive positive pressure ventilation, standard medical treatments were delivered to these patients according to guidelines. The need for endotracheal intubation was judged as failure of non-invasive ventilation treatment. Early failure was defined as the need for endotracheal intubation within 48 hours of treatment, and late failure was defined as the need for endotracheal intubation 48 hours and later. The HACOR score at different time points after non-invasive ventilation, the length of intensive care unit (ICU) stay, the total length of hospital stay, and the clinical outcome were recorded. The above indexes of patients with non-invasive ventilation were compared between successful and failed groups. The receiver operator characteristic curve (ROC curve) was drawn to evaluate the predictive effect of HACOR score on the failure of non-invasive positive pressure ventilation in the treatment of COPD with pulmonary encephalopathy.
RESULTS: A total of 630 patients were evaluated, and 51 patients were enrolled, including 42 males (82.35%) and 9 females (17.65%), with a median age of 70.0 (62.0, 78.0) years old. Among the 51 patients, 36 patients (70.59%) were successfully treated with non-invasive ventilation and discharged from the hospital eventually, and 15 patients (29.41%) failed and switched to invasive ventilation, of which 10 patients (19.61%) were defined early failure, 5 patients (9.80%) were late failure. The length of ICU and the total length of hospital stay of the non-invasive ventilation successful group were significantly longer than those of the non-invasive ventilation failure group [length of ICU stay (days): 13.0 (10.0, 16.0) vs. 5.0 (3.0, 8.0), total length of hospital stay (days): 23.0 (12.0, 28.0) vs. 12.0 (9.0, 15.0), both P < 0.01]. The HACOR score of patients at 1-2 hours in the non-invasive ventilation failure group was significantly higher than that in the successful group [10.47 (6.00, 16.00) vs. 6.00 (3.25, 8.00), P < 0.05]. However, there was no significant difference in HACOR score before non-invasive ventilation and at 3-6 hours between the two groups. The ROC curve showed that the area under the ROC curve (AUC) of 1-2 hour HACOR score after non-invasive ventilation for predicting non-invasive ventilation failure in COPD patients with pulmonary encephalopathy was 0.686, and the 95% confidence interval (95%CI) was 0.504-0.868. When the best cut-off value was 10.50, the sensitivity was 60.03%, the specificity was 86.10%, positive predictive value was 91.23%, and negative predictive value was 47.21%.
CONCLUSIONS: Non-invasive positive pressure ventilation could prevent 70.59% of COPD patients with pulmonary encephalopathy from intubation. HACOR score was valuable to predict non-invasive positive pressure ventilation failure in pulmonary encephalopathy patients due to COPD.
参考来源
- Zhang W, Gao S, Yang Y, et al. [Predictive value of HACOR score on the clinical outcome of non-invasive positive pressure ventilation in the treatment of chronic obstructive pulmonary disease with pulmonary encephalopathy]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023. PMID: 36916371. doi:10.3760/cma.j.cn121430-20220531-00515
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。